ABBV · News · 20260923N
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-09-23 · Importance 58 · Surprise 42 · In source text
AbbVie reportedly pursued the acquisition of Apogee Therapeutics through an $8.0 billion public offering. The transaction is positioned as part of AbbVie’s strategy to expand its drug portfolio and support growth beyond Humira. The reported offering amount exceeds the company’s $510 million materiality threshold.
Key facts
- AbbVie is pursuing the acquisition of Apogee Therapeutics supported by an $8.0 billion public offering. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | probable | +3.0% | AbbVie is pursuing the acquisition of Apogee Therapeutics supported by an $8.0 billion public offering. |
| assets | positive | probable | — | AbbVie is pursuing the acquisition of Apogee Therapeutics supported by an $8.0 billion public offering. |